+46.1%
GSK vs NTRS
+168.2%
-122.0%
-28.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | NTRS | Excess | Alpha |
|---|---|---|---|---|
| 1D | 0.0% | +1.1% | -1.0% | -0.1% |
| 7D | -3.5% | +1.4% | -4.9% | -3.7% |
| 30D | -3.4% | -0.7% | -2.8% | -3.4% |
| 3M | -8.1% | +11.3% | -19.4% | -9.1% |
| 6M | -11.1% | +35.5% | -46.7% | -13.7% |
| YTD | +0.7% | +40.6% | -39.9% | -2.6% |
| 1Y | +20.1% | +49.2% | -29.1% | +15.6% |
| 3Y | +46.1% | +167.2% | -121.1% | +32.8% |
| All | +46.1% | +168.2% | -122.0% | +32.8% |
Cumulative growth
Daily Returns
Daily percentage return beside NTRS.
Daily Out/Under-Performance
Portfolio return minus NTRS return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × NTRS return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded NTRS wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling